Koda Yuki
Otolaryngology-Head and Neck Surgery, Osaka Metropolitan University, Osaka, JPN.
Cureus. 2025 Jul 24;17(7):e88643. doi: 10.7759/cureus.88643. eCollection 2025 Jul.
This study evaluates the effectiveness of Goreisan, a traditional Kampo medicine, in treating Ménière's disease (MD), focusing on vertigo frequency, dizziness severity, and hearing function.
A retrospective analysis was conducted on 164 patients diagnosed with definite MD between April 2017 and March 2022. Among them, 52 patients received Goreisan treatment, while 31 patients did not receive any diuretic therapy. Vertigo frequency, Dizziness Handicap Inventory (DHI) scores, and hearing function were assessed over a 12-month period.
Patients in the Goreisan group showed a significant reduction in vertigo frequency at two, six, and 12 months, whereas the no-medication group showed significant improvement only at two months. DHI scores improved in both groups, suggesting that betahistine and lifestyle modifications may contribute to symptom relief. No significant changes in hearing function were observed in the Goreisan group.
Goreisan may be an effective and safe treatment option for reducing vertigo frequency in MD patients. However, it does not appear to improve hearing function. Further placebo-controlled studies are needed to confirm its efficacy.
本研究评估汉方传统药物五苓散治疗梅尼埃病（MD）的有效性，重点关注眩晕频率、头晕严重程度和听力功能。
对2017年4月至2022年3月期间确诊为明确MD的164例患者进行回顾性分析。其中，52例患者接受五苓散治疗，31例患者未接受任何利尿剂治疗。在12个月的时间里评估眩晕频率、头晕残障量表（DHI）评分和听力功能。
五苓散组患者在2个月、6个月和12个月时眩晕频率显著降低，而未用药组仅在2个月时有显著改善。两组的DHI评分均有所改善，表明倍他司汀和生活方式的改变可能有助于缓解症状。五苓散组未观察到听力功能有显著变化。
五苓散可能是减少MD患者眩晕频率的一种有效且安全的治疗选择。然而，它似乎并不能改善听力功能。需要进一步的安慰剂对照研究来证实其疗效。
